Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. more
Time Frame | TNFA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.24% | 2.44% | 2.58% |
1-Month Return | -4.44% | -4.49% | 0.09% |
3-Month Return | -22.75% | -8.82% | 4.76% |
6-Month Return | -31.75% | -4.46% | 9.89% |
1-Year Return | -81.93% | 3.16% | 26.47% |
3-Year Return | -99.25% | -0.83% | 25.98% |
5-Year Return | -99.33% | 35.65% | 86.34% |
10-Year Return | -100% | 101.94% | 189.21% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | 29.45K | - | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Profit | (29.45K) | - | - | - | [{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 12.26M | 28.20M | 15.28M | 17.12M | [{"date":"2020-12-31","value":43.46,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":54.19,"profit":true},{"date":"2023-12-31","value":60.72,"profit":true}] | |
Operating Income | (12.29M) | (28.20M) | (15.28M) | (17.12M) | [{"date":"2020-12-31","value":-1228570000,"profit":false},{"date":"2021-12-31","value":-2820125000,"profit":false},{"date":"2022-12-31","value":-1528276000,"profit":false},{"date":"2023-12-31","value":-1712305200,"profit":false}] | |
Total Non-Operating Income/Expense | (1.19M) | (1.68M) | 169.42K | 13.58M | [{"date":"2020-12-31","value":-8.78,"profit":false},{"date":"2021-12-31","value":-12.36,"profit":false},{"date":"2022-12-31","value":1.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Pre-Tax Income | (12.15M) | (29.89M) | (15.20M) | (4.00M) | [{"date":"2020-12-31","value":-1215221400,"profit":false},{"date":"2021-12-31","value":-2988904500,"profit":false},{"date":"2022-12-31","value":-1519733600,"profit":false},{"date":"2023-12-31","value":-399995000,"profit":false}] | |
Income Taxes | 5.43M | (18.33K) | (15.28M) | (16.36M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-0.34,"profit":false},{"date":"2022-12-31","value":-281.53,"profit":false},{"date":"2023-12-31","value":-301.38,"profit":false}] | |
Income After Taxes | (17.58M) | (29.87M) | 85.43K | 12.36M | [{"date":"2020-12-31","value":-142.23,"profit":false},{"date":"2021-12-31","value":-241.67,"profit":false},{"date":"2022-12-31","value":0.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Income From Continuous Operations | (9.49M) | (29.89M) | (15.20M) | (4.00M) | [{"date":"2020-12-31","value":-948782400,"profit":false},{"date":"2021-12-31","value":-2988904500,"profit":false},{"date":"2022-12-31","value":-1519733600,"profit":false},{"date":"2023-12-31","value":-399995000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (17.58M) | (29.89M) | (15.20M) | (4.00M) | [{"date":"2020-12-31","value":-1758060900,"profit":false},{"date":"2021-12-31","value":-2988904500,"profit":false},{"date":"2022-12-31","value":-1519733600,"profit":false},{"date":"2023-12-31","value":-399995000,"profit":false}] | |
EPS (Diluted) | (299.36) | (32.47) | (11.77) | (5.65) | [{"date":"2020-12-31","value":-29936.13,"profit":false},{"date":"2021-12-31","value":-3246.57,"profit":false},{"date":"2022-12-31","value":-1177.47,"profit":false},{"date":"2023-12-31","value":-564.54,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
TNFA | |
---|---|
Cash Ratio | 1.52 |
Current Ratio | 1.72 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TNFA | |
---|---|
ROA (LTM) | -32.43% |
ROE (LTM) | -297.63% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TNFA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TNFA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.44 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
TNF Pharmaceuticals, Inc. (TNFA) share price today is $1.29
Yes, Indians can buy shares of TNF Pharmaceuticals, Inc. (TNFA) on Vested. To buy TNF Pharmaceuticals, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TNFA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of TNF Pharmaceuticals, Inc. (TNFA) via the Vested app. You can start investing in TNF Pharmaceuticals, Inc. (TNFA) with a minimum investment of $1.
You can invest in shares of TNF Pharmaceuticals, Inc. (TNFA) via Vested in three simple steps:
The 52-week high price of TNF Pharmaceuticals, Inc. (TNFA) is $10.68. The 52-week low price of TNF Pharmaceuticals, Inc. (TNFA) is $1.05.
The price-to-earnings (P/E) ratio of TNF Pharmaceuticals, Inc. (TNFA) is
The price-to-book (P/B) ratio of TNF Pharmaceuticals, Inc. (TNFA) is 0.44
The dividend yield of TNF Pharmaceuticals, Inc. (TNFA) is 0.00%
The market capitalization of TNF Pharmaceuticals, Inc. (TNFA) is $3.13M
The stock symbol (or ticker) of TNF Pharmaceuticals, Inc. is TNFA